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tom measure, UGI distress, was developed using WHO
adverse event codes (abdominal pain, nausea, and dyspep-
sia). To simulate clinically significant adverse events re-
quiring medical intervention, only moderate (some limita-
tion of activities) and severe (inability to carry out
activities) events were included. Survival analysis was
used to calculate the cumulative percentage of patients
with UGI distress over a 12-week period.
RESULTS: Kaplan-Meier curves revealed a significant
difference (p  0.01) between NSAIDs compared to pla-
cebo and/or celecoxib. At 12 weeks, the cumulative prob-
ability of patients to have UGI distress were: NSAIDs
(12.9%), celecoxib (8.1%), and placebo (8.5%) (p 
0.01 for NSAIDs versus celecoxib or placebo; p  NS for
celecoxib versus placebo).
CONCLUSION: NSAID-treated patients experience sig-
nificant UGI distress beyond the background rate of UGI
distress, as represented by placebo. These results demon-
strate the clinical advantage of celecoxib over existing
NSAIDs and suggest a potential healthcare utilization ad-
vantage due to decreased frequency of UGI distress and
need for physician intervention.
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OBJECTIVE: To compare the efficacy and economic
outcomes related to the treatment of acute bacterial exac-
erbation of chronic bronchitis in adult patients treated
with either: 1) cefpodoxime proxetil 100mg, or 2) cefpo-
doxime proxetil 200mg twice daily for 14 days.
METHODS: The cefpodoxime proxetil arms of a multi-
center, randomized, observer-blinded, parallel-group an-
tibiotic trial were evaluated. A total of 117 patients com-
pleted the study (100mg n  58, 200mg n  59). Direct
and indirect costs related to the infection and its treat-
ment were collected over the course of the study, includ-
ing additional office visits, lab tests and procedures, and
indirect costs related to productivity changes at work and
social hours lost due to the illness.
RESULTS: There were no significant differences between
the 100mg and 200mg groups with regards to bacterial
cure rates (89.7% and 89.8%, respectively), mean per-
cent of total work hours lost (16.91 [15.67] and 20.47
[27.41], respectively [p  0.597], and mean percent of
total social hours lost (10.71 [12.69] and 9.55 [9.67], re-
spectively [p  0.690]). Furthermore, there were no prac-
tical differences in the additional healthcare utilization
and number of medical events related to the drug ther-
apy. Mean study medication costs were significantly
lower (p  0.001) for the 100mg group ($66.70 [$6.80])
when compared to the 200mg group ($93.80 [$5.72]).
CONCLUSIONS: Because there were no significant dif-
ferences in the clinical outcomes, additional health utili-
zation and medical events, and work and social hours
lost when comparing the two treatment regimens, the use
of cefpodoxime proxetil 100mg provided cost-minimiza-
tion over cefpodoxime proxetil 200mg in the treatment
of acute bacterial exacerbation of chronic bronchitis in
adult patients.
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OBJECTIVES: To develop and validate a disease-specific
questionnaire to measure the impact of urinary inconti-
nence (UI) in women’s quality of life (QoL). This ques-
tionnaire is aimed at measuring all types of incontinence
in clinical trials. A urinary urge incontinence (UUI) ques-
tionnaire already available and fully validated was used
as a basis.
METHODS: 1) Identification of additional measurement
concepts, during 12 interviews. 2) Item generation fol-
lowing the existing questionnaire format. 3) Content and
face validity in additional interviews. 4) Cross-sectional
validation study: to allow item reduction (based on ho-
mogeneity of the domains, item rank and fit in the Rasch
modeling), to assess the construct validity (multitrait
analysis), internal consistency and clinical validity. 5)
Test-retest reliability study.
RESULTS: In this study 104 patients with urge, stress,
and mixed UI filled in the specific questionnaire once. Pa-
tients were 50 years old on average, 40% had urge-related
urinary leakage several times a week, 34% had micturi-
tions at night, 73% had stress-related leakage during light
and moderate efforts. The initial 50-item questionnaire
was reduced to 28 items gathered in six dimensions: daily
activities, effort situation, self-image, emotional impact,
sexuality, and global QoL. Item grouping hypotheses
proved relevant based on item convergent and divergent
validity and internal reliability (Cronbach’s alpha 
0.76). Clinical validity was demonstrated by the signifi-
cant impairment of QoL in patients reporting urinary
leaks, greater urge-related and stress-related urinary
handicap (p  0.0005). Fifty-eight stable women filled in
the questionnaire twice. Intraclass Correlation Coeffi-
cients ranged from 0.87 to 0.94, showing good test-retest
reproducibility.
